margins. Median follow up was 36 months. There were 5.8% of patients diagnosed with recurrence. Grade, stage, surgical margins, and R.E.N.A.L score were associated with shorter disease-free survival (DFS). In multivariable regression pT (p<0.01), grade (p<0.01), and R.EN.A.L score (p¼0.02) remain independent predictors of DFS. pT stage (HR 4.9, p<0.01) and grade (HR 3.9, p<0.01) were predictors of metastasis, while R.E.N.A.L score (HR 3.86, p¼0.03) was the single predictor of local recurrence. Positive surgical margin did not predict recurrence. Five-year DFS and OS probabilities were 91% and 94%, respectively. Local recurrence emerged and developed earlier than metastasis (median 13 vs. 22 months, p<0.01).
INTRODUCTION AND OBJECTIVES: pT3a disease is known to represent a poor prognostic factor in renal cell carcinoma (RCC) with an approximate four-fold increased risk for recurrence regardless of size when compared to pT1 disease. The impact of incidental pT3a upstaging in patients undergoing partial nephrectomy (PNx) for cT1 disease, however, is not well defined.
METHODS: A retrospective chart review was completed at the University of Michigan and Moffitt Cancer Center to identify patients who underwent PNx between 1996-2015 for cT1 RCC with subsequent pathologic upstaging to pT3a disease. Patients with pT3a disease were compared to controls who underwent PNx for cT1 disease with final pathology confirming pT1 disease. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were estimated using the Kaplan-Meier method.
RESULTS: A total of 95 patients with pT3a upstaging were identified and compared to 1164 controls. Median follow up in our series was 38.2 (IQR 11.6-56.8) months. Following PNx, 20 (21%) patients with incidental pT3a upstaging suffered disease recurrence at a median of 28.7 months (IQR 10.3-43.5), consisting of 4 (4%) local recurrences and 17 (18%) distant metastases. In comparison, 8 (0.7%) controls suffered disease recurrence at a median of 46.6 months . In patients with pT3a disease, the 5-and 8-year RFS was 71% and 59%, compared to 88% and 78% in controls (p<0.0001). CSS was also significantly different between cohorts, with pT3a patients experiencing a 5-and 8-year CSS of 92% and 79%, compared to 99% and 98% in controls (p¼0.001). Kaplan-Meijer curves are depicted in Figure  1 . There were a total of 7 (7%) RCC related deaths, which occurred at a median of 28.5 months (IQR 9.3-54.3) in the pT3a cohort, while there were 5 (0.4%) RCC related deaths at a median of 96.5 months (IQR 56.9-96.9) in those with final pT1 disease.
CONCLUSIONS: The data presented here suggests that patients with cT1 disease and incidental pT3a upstaging following PNx experience a significantly reduced RFS and CSS compared to those with final pT1 disease, and thus may benefit from modified follow up protocols or early adjuvant therapies.
Source of Funding: None

MP72-07 HISTOPATHOLOGIC ANALYSIS OF TUMOR BED AFTER IN VITRO TUMOR ENUCLEATION ON RADICAL NEPHRECTOMY SPECIMEN
Qun Lu*, Changwei Ji, Xiaozhi Zhao, Guangxiang Liu, Hongqian Guo, Nanjing, China, People's Republic of INTRODUCTION AND OBJECTIVES: In recent years, large series of tumor enucleation (TE) for renal masses have showed equivalent functional and oncological results compared with standard partial nephrectomy. However, few objective assessments and pathologic evidence of enucleation tumor bed have been reported. This study was designed to assess the feasibility and histopathologic safety of tumor enucleation for renal cell carcinoma, through histopathologic analysis of the tumor bed after in vitro tumor enucleation.
METHODS: We studied 246 radical nephrectomy specimens for clinical T1 RCC in our institution, from January 2013 to December 2015. Immediately after the kidney was excised, the tumor of radical specimen was enucleated in vitro in the same fashion as open or e956 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 laparoscopic kidney tumor enucleation. The tumor bed parenchyma of 15 mm beyond the pseudocapsule were continuously sectioned and examined to investigate the possible presence of tumor invasion or satellite lesions. RESULTS: The study involved 246 patients, consisting of 148 men (60.2%) and 98 women (39.8%), with a mean age of 60.9AE10.3 years. The average tumor size was 5.3AE1.7 cm. The histopathologic evaluation revealed that 82.5% of tumors were clear cell RCC, 7.7% were papillary, and 6.5% were chromophobe. The pathological staging showed that 23.2% of tumors were pT1a, 68.3% were pT1b, 3.7% were pT2, and 4.9% were pT3a. On the basis of Fuhrman nuclear grading, 171 lesions (69.5%) were grade 1-2 and 75 (30.5%) were grade 3-4. The incidence of positive surgical margins was 3.3%. For the pathological characteristics of tumor bed, tumor infiltration was detected in 5 cases (2.0%) and satellite lesion was detected in 4 cases (1.6%). In the group of 60 primary tumors 4 cm or less in diameter, 3 (5.0%) were found with residual tumor, 1 with tumor infiltration and 2 with satellite lesion. In the group of 186 primary tumors larger than 4 cm, 6 (3.2%) were found with residual tumor, 4 with tumor infiltration and 2 with satellite lesion. Statistically, there was no significant difference (p¼0.809). In the group of grade 1-2, 4 (2.3%) were found with residual tumor, and 5 (6.7%) in the group of grade 3-4 (p¼0.195). Median followup was 24 months (range 8-43) with a recurrence rate of 4.1% (10 of 246) and a cancer specific mortality rate of 2.4% (6 of 246).
CONCLUSIONS: The risks of tumor infiltration and/or satellite lesions of enucleation tumor bed are relatively low. Tumor enucleation is a histopathologically safe technique for patients undergoing partial nephrectomy. 
Source of Funding
INTRODUCTION AND OBJECTIVES:
Chronic kidney disease has significant implications on patient outcomes. Proteinuria along with glomerular filtration rate is increasing used as a marker for kidney disease. The relationship between pre-operative proteinuria and survival following nephrectomy is incompletely characterized. Herein, we evaluated the association of preoperative proteinuria with overall and cancer-specific survival in our institutional nephrectomy registry.
METHODS: We identified patients with clear cell renal cell carcinoma treated for curative intent from 1995 to 2010. Patients were categorized based on KDIGO (Kidney Disease Improving Global Outcomes) 2012 guidelines. Overall and cancer-specific survivals were evaluated using Kaplan-Meier methodology. Cox proportional hazards regression models were used to assess for variables associated with overall and cancer-specific mortality.
RESULTS: Between 1995 and 2010, 1,846 patients underwent radical or partial nephrectomy. Of these, 1,347 (73%) underwent preoperative predicted 24-hour urine protein testing. Patients with and without predicted 24-hour urine protein had no difference in overall survival (p¼0.73) or cancer-specific survival (p¼0.85). There were 804 (60%) patients classified with mild (<150 mg/day), 332 (25%) classified with moderate (150-500 mg/day), and 211 (16%) classified with severe proteinuria (>500 mg/day). Kaplan-Meier overall survival curves stratified by pre-operative proteinuria severity are depicted in the Figure  (p<0.001) . Multivariate analysis demonstrated severe proteinuria was associated with worse overall survival (HR 1.61 95%CI 1.26-2.07 p<0.001). Proteinuria level was not associated with worse cancerspecific survival.
CONCLUSIONS: Severe pre-operative proteinuria is associated with worse overall survival. During patient counseling, pre-operative proteinuria should be considered when estimating a patient 0 s overall health risk. INTRODUCTION AND OBJECTIVES: Emerging data from centers of excellence suggests that partial nephrectomy (PN) for cT1b and cT2a Renal Cell Carcinoma (RCC) are oncologically safe and may confer renal functional benefit. We sought to study trends in utilization and short term quality outcomes of PN among patients with cT1b and cT2a RCC using the National Cancer Database (NCDB).
METHODS: We identified 39,561 patients with localized cT1b or cT2a RCC who underwent PN from 2004-2013. Primary outcome was utilization of PN over time. Secondary outcomes included hospital length of stay (LOS, short hospitalization: 0-4 days), margin status and 30-day readmissions. Cochrane-Armitage test was used to describe trends over time. Multivariable (MVA) logistic regression models were used to investigate associations between tumor stage and outcomes.
RESULTS: The study consisted of 28,620 (72.3%) patients with cT1b and 10,941 (27.7%) with cT2a masses. Overall, 8,953 (22.6%) patients underwent PN. More patients with cT1b vs. cT2a tumors underwent PN (28.1% vs. 8.34%; p<0.01). PN increased over the study period (cT1b: 13.7% to 37.1%, p<0.01; cT2a: 3.2% to 11.0%, p<0.01; Figure) . For all PN, positive margin rates increased from 4.3% in 2004 to 6.8% in 2013, (p<0.01); 30-day readmission was not significantly changed (2.2% in 2004 to 5.1% in 2013, p¼0.76). Proportion of short LOS increased, from 51.6% in 2004 to 75.2% in 2013 (p<0.01). MVA for positive margins was notable for increasing age (OR 1.01, p¼0.012), year of diagnosis (OR 1.07, p¼0.01), and facility type (comprehensive community OR 1.362, p¼0.002, integrated network cancer program OR 1.53, p¼0.009, free standing cancer center program OR 3.44, p¼0.003). MVA for 30-day readmission demonstrated high Charlson score (OR 1.38, p¼0.046), and facility type (integrated network cancer program OR 0.56, p¼0.022) as being significant. On MVA, patients with cT2a tumors were no more likely than those with cT1b to require 30-day readmission (OR 0.86, p¼0.36) or have positive margins (OR 0.96, p¼0.75) .
CONCLUSIONS: Utilization of PN for cT1b and cT2a renal mass has increased over time. While length of hospital stay has shortened and 30-day readmission rates are not significantly different, an increase in positive margin rates has been noted, with predictive factors including patient age and facility type. PN in cT2a does not confer increased risk compared to PN in cT1b RCC. Focused emphasis
